MASI

Masimo Corporation

Fundamental data last updated:August 19, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.

 


VALUATION

P/E

122.07

Market Cap ($M USD)

$9.34B

Forward P/E

24.01

PEG

0.06

PRICE TO SALES

6.00

PRICE TO BOOK

11.81

EV / EBITDA

28.17

5-Year Average P/E

Free Cash Flow Yield

2.23%

DCF Value

$31.29

Graham Number

$22.29

Price to FCF

44.75

EV to FCF

46.48

Earnings Yield

0.82%

FCF Yield

2.23%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.46

Next Year EPS Growth Estimate

$7.43

Next Year Revenue Growth Estimate

$1.97B

Return on Equity (ROE)

9.08%

FREE CASH FLOW

Operating Margin

19.85%

Debt-to-Equity

0.78

Piotroski F-Score

8

Altman Z-Score

9.73

Return on Invested Capital (ROIC)

23.49%

Current Ratio

2.68

Quick Ratio

1.45

Net Debt to EBITDA

1.05

Interest Coverage

10.11

Gross Profit margin

61.73%

FCF PER SHARE

$4.00

REVENUE PER SHARE

$29.86

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing Masimo Corporation significantly. With a DCF value far below the snapshot price, the stock appears extended. The Forward P/E of 24 suggests optimism about future earnings, yet the earnings yield of just 0.82% indicates a low return on investment at current prices. However, the Altman Z-score of 9.71 signals strong financial health, suggesting low bankruptcy risk. This juxtaposition of high valuation and robust safety metrics creates a complex narrative for investors.

AI Exposure / Tech Reliance

Operating in the Medical Instruments & Supplies industry, Masimo is well-positioned to leverage AI and tech advancements. The healthcare sector's increasing reliance on data analytics and precision instruments aligns with Masimo's core competencies. This positioning could enhance their product offerings and operational efficiency in the evolving tech landscape.

The Bull Case

For the value-driven investor, Masimo presents a compelling case. The ROIC of 23.49% highlights exceptional capital efficiency, while a Piotroski F-Score of 8 indicates solid financial health. Despite a modest FCF yield of 2.24%, the company's operating margin of 19.85% underscores its pricing power. These metrics suggest a company capable of generating strong returns on invested capital, making it attractive for those seeking growth at a reasonable price.

The Bear Case

Yet, the stock's valuation metrics raise red flags. A Price/Book ratio of 11.80 and Price/Sales of 5.99 suggest it is priced for perfection, leaving little room for error. The proximity to its 52-week high, just 0.39% away, indicates potential overextension. Additionally, the EV to FCF ratio of 46.45 points to a premium valuation that may not be justified by its cash flow generation. These factors could pose significant risks for investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$187.50

Institutional Ownership %

1-Year Beta

1.13

Insider Buying % (6 Mo)

Distance to 52-Week High

0.32%

Distance to 52-Week Low

29.42%

EARNINGS SURPRISE %

-21.99%

50-DAY SMA

$178.35

200-DAY SMA

$154.75

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.